Total Payments
$200,716
2024 Payments
$230.33
Companies
5
Transactions
72
Medicare Patients
982
Medicare Billing
$184,169
Payment Breakdown by Category
Consulting$178,543 (89.0%)
Other$21,645 (10.8%)
Food & Beverage$528.01 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $178,543 | 57 | 89.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $21,645 | 8 | 10.8% |
| Food and Beverage | $528.01 | 7 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Foundation Medicine, Inc. | $185,531 | 62 | $0 (2023) |
| Genentech USA, Inc. | $9,062 | 3 | $0 (2023) |
| Servier BioInnovation | $3,740 | 1 | $0 (2023) |
| Eisai Inc. | $2,152 | 4 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $230.33 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $230.33 | 2 | AstraZeneca Pharmaceuticals LP ($230.33) |
| 2023 | $36,599 | 16 | Foundation Medicine, Inc. ($21,645) |
| 2022 | $42,458 | 12 | Foundation Medicine, Inc. ($42,458) |
| 2021 | $44,250 | 11 | Foundation Medicine, Inc. ($44,250) |
| 2020 | $34,875 | 11 | Foundation Medicine, Inc. ($34,875) |
| 2019 | $27,904 | 12 | Foundation Medicine, Inc. ($27,904) |
| 2018 | $11,600 | 6 | Foundation Medicine, Inc. ($11,600) |
| 2017 | $2,800 | 2 | Foundation Medicine, Inc. ($2,800) |
All Payment Transactions
72 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/02/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $119.54 | General |
| Category: Oncology | ||||||
| 02/08/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $110.79 | General |
| Category: Oncology | ||||||
| 12/08/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,462.50 | General |
| Category: Oncology | ||||||
| 12/01/2023 | Servier BioInnovation | Asparlas (Drug) | Consulting Fee | Cash or cash equivalent | $3,740.00 | General |
| Category: Oncology | ||||||
| 10/04/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,340.00 | General |
| Category: Oncology | ||||||
| 08/01/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,340.00 | General |
| Category: Oncology | ||||||
| 07/19/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,510.00 | General |
| Category: Oncology | ||||||
| 05/03/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,755.00 | General |
| Category: Oncology | ||||||
| 04/14/2023 | Genentech USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $6,080.00 | General |
| 03/31/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,510.00 | General |
| Category: Oncology | ||||||
| 03/09/2023 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $2,040.00 | General |
| Category: Oncology | ||||||
| 03/07/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,387.50 | General |
| Category: Oncology | ||||||
| 02/23/2023 | Genentech USA, Inc. | Tecentriq (Biological) | Consulting Fee | Cash or cash equivalent | $2,850.00 | General |
| Category: BioOncology | ||||||
| 02/23/2023 | Genentech USA, Inc. | Tecentriq (Biological) | Food and Beverage | In-kind items and services | $131.92 | General |
| Category: BioOncology | ||||||
| 02/22/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| Category: Oncology | ||||||
| 02/22/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| Category: Oncology | ||||||
| 02/22/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $12.12 | General |
| Category: Oncology | ||||||
| 02/02/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,340.00 | General |
| Category: Oncology | ||||||
| 12/28/2022 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $877.50 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2022 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $2,340.00 | General |
| Category: ONCOLOGY | ||||||
| 12/08/2022 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $4,095.00 | General |
| Category: Oncology | ||||||
| 12/05/2022 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $1,755.00 | General |
| Category: Oncology | ||||||
| 11/29/2022 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $1,462.50 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2022 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $2,632.50 | General |
| Category: ONCOLOGY | ||||||
| 06/21/2022 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $2,047.50 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 183 | 256 | $126,157 | $24,641 |
| 2022 | 6 | 280 | 582 | $284,234 | $58,003 |
| 2021 | 5 | 254 | 552 | $254,628 | $60,032 |
| 2020 | 5 | 265 | 483 | $190,014 | $41,493 |
Total Patients
982
Total Services
1,873
Medicare Billing
$184,169
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 36 | 53 | $33,110 | $6,314 | 19.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 24 | 24 | $22,130 | $3,350 | 15.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 34 | 41 | $16,523 | $3,295 | 19.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 16 | 33 | $13,788 | $3,281 | 23.8% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 34 | 39 | $15,717 | $3,027 | 19.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 16 | 43 | $12,470 | $2,881 | 23.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 11 | 11 | $8,899 | $1,673 | 18.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 12 | 12 | $3,520 | $819.85 | 23.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 96 | 235 | $142,695 | $28,452 | 19.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 47 | 149 | $61,066 | $12,975 | 21.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 52 | 81 | $32,295 | $6,384 | 19.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 28 | 29 | $22,945 | $4,898 | 21.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 36 | 52 | $20,655 | $4,305 | 20.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 21 | 36 | $4,578 | $988.82 | 21.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 104 | 269 | $141,519 | $34,141 | 24.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 67 | 122 | $41,159 | $10,138 | 24.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 24 | 91 | $37,793 | $7,877 | 20.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 23 | 23 | $18,579 | $3,987 | 21.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 36 | 47 | $15,578 | $3,890 | 25.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 37 | 124 | $51,920 | $11,245 | 21.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 71 | 122 | $63,252 | $11,128 | 17.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 76 | 137 | $28,735 | $9,413 | 32.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 29 | 29 | $23,602 | $5,104 | 21.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 52 | 71 | $22,505 | $4,603 | 20.5% |
About Dr. Joseph Franses, MD
Dr. Joseph Franses, MD is a Hematology & Oncology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/05/2013. The National Provider Identifier (NPI) number assigned to this provider is 1861830416.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joseph Franses, MD has received a total of $200,716 in payments from pharmaceutical and medical device companies, with $230.33 received in 2024. These payments were reported across 72 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($178,543).
As a Medicare-enrolled provider, Franses has provided services to 982 Medicare beneficiaries, totaling 1,873 services with total Medicare billing of $184,169. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Chicago, IL
- Active Since 06/05/2013
- Last Updated 05/22/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1861830416
Products in Payments
- FOUNDATIONONE CDX (Device) $134,978
- FOUNDATIONONE LIQUID (Device) $47,700
- Asparlas (Drug) $3,740
- Tecentriq (Biological) $2,982
- FOUNDATIONACT (Device) $2,854
- Lenvima (Drug) $2,152
- IMFINZI (Biological) $230.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Chicago
Michael Bishop
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Young Kwang Chae, Md, Mph, Mba, MD, MPH, MBA
Hematology & Oncology — Payments: $682,642
Hematology & Oncology $682,642
Irfan Mirza, Md, MD
Hematology & Oncology — Payments: $644,273
Hematology & Oncology $644,273
Everett Vokes
Hematology & Oncology — Payments: $449,910
Hematology & Oncology $449,910
Peter Riedell
Hematology & Oncology — Payments: $374,919
Hematology & Oncology $374,919
Rita Nanda
Hematology & Oncology — Payments: $374,678
Hematology & Oncology $374,678